DAFTAR PUSTAKA

Benarroch, E. E. (2012). Insulin-like growth factors in the brain and their potential clinical implications. *Neurology*, *79*(21), 2148-2153.

Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Pecorini, G., Landolfi, R. and Flex, A. (2019) 'High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives', *International Journal of Molecular Sciences*, 20(24), p. 6258. doi: 10.3390/ijms20246258.

Caplan, L.R. (2016) *Caplan's Stroke A Clinical Approach*. Fifth Edit. Cambridge University Press.

Chen, H., Guan, B., Wang, B., Pu, H., Bai, X., Chen, X., et al., 2020. Glycyrrhizin prevents hemorrhagic transformation and improves neurological outcome in ischemic stroke with delayed thrombolysis through targeting peroxynitrite-mediated HMGB1 signaling. *Translational Stroke Research*, 11, pp.967–982. https://doi.org/10.1007/s12975-019-00772-1

Chen, R., Kang, R. and Tang, D. (2022) 'The mechanism of HMGB1 secretion and release', *Experimental & Molecular Medicine*, 54(2), pp. 91–102. doi: 10.1038/s12276-022-00736-w.

Dyer, A. H., Vahdatpour, C., Sanfeliu, A., & Tropea, D. (2016). The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticity. *Neuroscience*, *325*, 89-99.

Hu, J., Liu, B., Zhao, Q., Jin, P., Hua, F., Zhang, Z., Liu, Y., Zan, K., Cui, G. and Ye, X. (2016) 'Bone marrow stromal cells inhibits HMGB1-mediated inflammation after stroke in type 2 diabetic rats', *Neuroscience*, 324, pp. 11–19. doi: 10.1016/j.neuroscience.2016.02.058.

Kemenkes RI. (2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/394/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Stroke.

Kwak, M.S., Kim, H.S., Lee, B., Kim, Y.H., Son, M. and Shin, J.S., 2020. Immunological significance of HMGB1 post-translational modification and redox biology. *Frontiers in Immunology*, 11, p.1189. https://doi.org/10.3389/fimmu.2020.01189

Liu, K., Mori, S., Takahashi, H.K., Tomono, Y., Wake, H., Kanke, T., Sato, Y., Hiraga, N., Adachi, N., Yoshino, T. and Nishibori, M., 2007. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. *FASEB Journal*, 21(14), pp.3904–3916. https://doi.org/10.1096/fj.07-8770com

Liu, Z., Yang, W., Chen, J. and Wang, Q. (2024) 'Circulating HMGB1 in acute ischemic stroke and its association with post-stroke cognitive impairment', PeerJ, 12, e17309. doi: 10.7717/peerj.17309.

Majumder, D. (2024) 'Ischemic stroke: Pathophysiology and evolving treatment approaches', *Neuroscience Insights*, 19. doi:10.1177/26331055241292600.

Mao, D., Zheng, Y., Xu, F., Han, X. and Zhao, H., 2022. HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target. *Frontiers in Neurology*, 13, p.1029891. https://doi.org/10.3389/fneur.2022.1029891

Mosenzon, O., Cheng, A.Y., Rabinstein, A.A. and Sacco, S. (2023) 'Diabetes and stroke: What are the connections?', *Journal of Stroke*, 25(1), pp. 26–38. doi:10.5853/jos.2022.02306.

Murphy SJ, Werring DJ. Stroke: causes and clinical features. Medicine (Abingdon). 2020 Sep;48(9):561-566. doi: 10.1016/j.mpmed.2020.06.002. Epub 2020 Aug 6. PMID: 32837228; PMCID: PMC7409792.

Nass RD, Wagner M, Surges R, Holdenrieder S. Time courses of HMGB1 and other inflammatory markers after generalized convulsive seizures. Epilepsy Res. 2020 May;162:106301. doi: 10.1016/j.eplepsyres.2020.106301. Epub 2020 Feb 26. PMID: 32126476.

Nishibori, M., Mori, S. and Takahashi, H.K., 2019. Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases. *Journal of Pharmacological Sciences*, 140, pp.94–101. https://doi.org/10.1016/j.jphs.2019.04.006

Nishibori, M., Wang, D., Ousaka, D. and Wake, H., 2020. High mobility group box-1 and blood-brain barrier disruption. *Cells*, 9(12), p.2650. https://doi.org/10.3390/cells9122650

Qiu, J., Nishimura, M., Wang, Y., Sims, J.R., Qiu, S., Savitz, S.I., Salomone, S. and Moskowitz, M.A. (2008) 'Early release of HMGB-1 from neurons after the onset of brain ischemia', *Journal of Cerebral Blood Flow & Metabolism*, 28, pp. 927–938. doi: 10.1038/sj.jcbfm.9600582.

Sacco, R.L., Kasner, S.E., Broderick, J.P., Caplan, L.R., Connors, J.J., Culebras, A., Elkind, M.S., George, M.G., Hamdan, A.D., Higashida, R.T., Hoh, B.L., Janis, L.S., Kase, C.S., Kleindorfer, D.O., Lee, J.M., Moseley, M.E., Peterson, E.D., Turan, T.N., Valderrama, A.L. and Vinters, H.V., on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, and Council on Nutrition, Physical Activity and Metabolism (2013) 'An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association', *Stroke*, 44(7), pp. 2064–2089.

Schulze, J., Zierath, D., Tanzi, P., Cain, K., Shibata, D., Dressel, A. and Becker, K. (2013) 'Severe stroke induces long-lasting alterations of high-mobility group box 1', *Stroke*, 44(1), pp. 246–248. doi:10.1161/STROKEAHA.112.676072.

Velez, L., Toffel, S., Trejo-Lopez, J., Kresak, J. L., & Beal, S. G. (2020). Educational case: etiologies, mechanisms, and treatment of stroke. *Academic Pathology*, *7*, 2374289520901817.

Wang, Y., Zhong, J., Zhang, X., Liu, Z., Yang, Y., Gong, Q. and Ren, B. (2016) 'The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes', Journal of Diabetes Research, 2016, Article ID 2543268. doi: 10.1155/2016/2543268.

Woodruff, T.M., Thundyil, J., Tang, S.C., Sobey, C.G., Taylor, S.M. and Arumugam, T.V., 2011. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. *Molecular Neurodegeneration*, 6(1), p.11. https://doi.org/10.1186/1750-1326-6-11

Xue, J., Suarez, J.S., Minaai, M., Li, S., Gaudino, G., Pass, H.I., Carbone, M. and Yang, H., 2021**.** HMGB1 as a therapeutic target in disease. *Journal of Cellular Physiology*, 236(5), pp.3406-3419. https://doi.org/10.1002/jcp.30125

Yahya, T., Jilani, M.H., Khan, S.U., Mszar, R., Hassan, S.Z., Blaha, M.J., Blankstein, R., Virani, S.S., Johansen, M.C., Vahidy, F., Cainzos-Achirica, M. and Nasir, K. (2020) 'Stroke in young adults: Current trends, opportunities for prevention and pathways forward', *American Journal of Preventive Cardiology*, 3, p. 100085. doi:10.1016/j.ajpc.2020.100085.

Ye Y, Zeng Z, Jin T, Zhang H, Xiong X and Gu L (2019) The Role of High Mobility Group Box 1 in Ischemic Stroke. Front. Cell. Neurosci. 13:127. doi: 10.3389/fncel.2019.00127

Zhang, J., Takahashi, H.K., Liu, K., Wake, H., Liu, R., Maruo, T., Date, I., Yoshino, T., Ohtsuka, A., Mori, S. and Nishibori, M., 2011. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. *Stroke*, 42(5), pp.1420–1428. https://doi.org/10.1161/STROKEAHA.110.598334

LAMPIRAN

Lampiran 1. Lembar skor NIHSS

LEMBAR NATIONAL INSTITUTES OF HEALTH STROKE SCORE

(NIHSS)

NAMA :

UMUR :

AKTIVITAS		Nilai		
		Onset hari ke 0-14	Keluar RS	Onset hari ke-30
1.a Derajat kesadaran	0= sadar penuh			
	1 = somnolen			
	2 = stupor			
	3 = koma			
1.b menjawab pertanyaan	0 = dapat menjawab 2 pertanyaan dengan benar (mis: bulan berapa dan usia)			
	1 =Hanya dapay menjawab 1 pertanyaan dengan benar/tidak dapat berbicara karena terpasang pipa endotrakeal			
	2= tidak bisa manjawab kedua pertanyaan dengan benar/ afasia/ stupor			
1. c Mengikuti perintah	0 = Dapat melakukan 2 perintah dengan benar (mis: buka mata dan tutup mata)			
	1 = Hanya dapat melakukan 1 perintah dengan benar			
	2 = Tidak dapat melakukan perintah dengan benar			
2. Gerakan mata konyugat horizontal	0 = Normal			
	1 = gerakan abnormal hanya pada satu mata			
	2 = deviasi konyugar yang kuat atau paresis konyugat total pada kedua mata			
3. Lapang	0= Tidak ada gangguan			

pandang	1 = Kuadranopia			
	2 = Hemianopia			
	3 = Hemianopia total			
	4 = Hemianopia bilateral/ buta kortikal			
4. Parese wajah	0 = Normal			
	1 = Paresis ringan			
	2 = Paresis parsial			
	3 = Paresis total			
5. Motorik lengan kanan	0 = Tidak ada simpangan bila pasien disuruh mengangkat lengannya selama 10 detik			
	1 = Langan menyimpang ke bawahn sebelum 10 detik			
	2 = Lengan terjatuh ke kasur atau badan atau tidak dapat diluruskan secara penuh			
	3 = Tidak dapat melawan gravitasi			
	4 = Tidak ada gerakan			
	X = Tidak dapat diperiksa			
6. Motorik lengan kiri	Idem No. 5			
7. Motorik tungkai kanan	Idem No. 5			
8. Motorik tungkai kiri	Idem No. 5			
9. Ataksia anggota badan	0 = Tidak ada			
	1 = Pada satu ekstremitas			
	2 = Pada dua ekstremitas			
	X = Tidak dapat diperiksa			
10. Sensorik	0 = Normal			
	1 = Defisit parsial yaitu merasa tai berkurang			
	2 = Defisit total yaitu pasien tidak merasa atau terdapat gangguan bilateral			
11. Bahasa terbaik	0 = Tidak ada afasia			
	1 = Afasia ringan-sedang			
	2 = afasia berat			

	X= tidak dapat bicara (bisu)/ afasia global/ koma			
12. Disartria	0 = Artikulasi normal			
	1 = Disartria ringan-sedang			
	2 = Disartria berat			
	X =tidak dapat diperiksa			
13. Neglect/ tidak ada atensi	0 = Tidak ada			
	1 = Parsial			
	2 =Total			
Nilai total				

Lampiran 2. Lembar skor mRS

Points	Grade of disability
0	No symptoms
1	No significant disability. Some symptoms but able to carry out all usual activities
2	Slight disability. Able to perform daily activity without assistance, but unable to carry out previous activities.
3	Moderate disability. Requires some help, unable to walk alone without assistance.
4	Moderate severe disability. Needs for assistance for own bodily needs, unable to walk alone without assistance.
5	Severe disability. Unable to attend own body needs without constant assistance, nursing care and attention. Incontinent.
6	Dead.

Lampiran 3. Izin Etik Penelitian

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 153/UN4.6.4.5.31/ PP36/ 2026

Tanggal: 27 Januari 2026

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH26010070	No Sponsor	
Peneliti Utama	**dr. Nurcholis**	Sponsor	
Judul Peneliti	Analisis Hubungan Kadar HMGB-1 Terhadap Severitas dan Luaran Klinis Pasien stroke iskemik Dengan Diabetes Melitus Tipe II dan Non Diabetes Melitus Tipe II		
No Versi Protokol	**1**	Tanggal Versi	**13 Januari 2026**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **27 Januari 2026** sampai **27 Januari 2027**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	**Prof. dr. Muh Nasrum Massi,PhD,SpMK, Subsp. Bakt(K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	**dr. Firdaus Hamid, PhD, SpMK(K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentuka